Studies presented at the recent International AIDS Conference demonstrate that combination therapy with inhibitors of the viral protease and reverse transcriptase produce profound and durable declines in the viral RNA present in plasma and increases in CD4 counts. Several investigators have even proposed that long term suppression with agents now available may result in eradication of virus and cure of disease. However, although these regimens produce very powerful antiviral effects in the short term, several features of drug dosing and medication adherence, viral replication, as well as pharmacokinetic variability may prevent the realization of this goal. First, the regimens require the administration of between 20 to 30 pills/day and must be taken over the course of at least several years. Second, variants resistant to all of these drugs have been described. Third, there is considerable variability both between and within individuals with regard to the drug levels maintained with the same does. Therefore, a major concern is the ability of HIV-infected people to take this large number of medications regularly over the long term; less than perfect adherence will no doubt be manifested at some time by the majority of patients. Fluctuating drug levels due to variable pharmacokinetics are also expected. We believe that over the long course of therapy anticipated for these compounds, each of these variables will play a role in determining their overall effectiveness. It is the impact of these factors on treatment efficacy and the development of antiviral resistance that is the focus of the studies proposed in this application. Specifically, we will: I. Test the hypothesis that altered patterns of medication adherence with protease inhibitors lead to the development of resistance and define the level of medication adherence necessary to maintain a clinically relevant antiviral effect. II. Identify the barriers to medication adherence. III. Define patient factors that influence the concentrations of protease inhibitors using minimally-invasive strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI041413-01A1
Application #
2431611
Study Section
AIDS and Related Research Study Section 6 (ARRF)
Project Start
1997-08-01
Project End
1998-04-30
Budget Start
1997-08-01
Budget End
1998-04-30
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Erlen, Judith A; Tamres, Lisa K; Reynolds, Nancy et al. (2015) Assessing usual care in clinical trials. West J Nurs Res 37:288-98
Petersen, Maya L; LeDell, Erin; Schwab, Joshua et al. (2015) Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring. J Acquir Immune Defic Syndr 69:109-18
Simoni, Jane M; Huh, David; Wang, Yan et al. (2014) The validity of self-reported medication adherence as an outcome in clinical trials of adherence-promotion interventions: Findings from the MACH14 study. AIDS Behav 18:2285-90
Rosen, M I; Black, A C; Arnsten, J H et al. (2013) Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. AIDS Behav 17:142-7
Wilson, Ira B; Bangsberg, David R; Shen, Jie et al. (2013) Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the multisite adherence collaboration on HIV 14 study. J Acquir Immune Defic Syndr 64:448-54
Liu, Honghu; Wilson, Ira B; Goggin, Kathy et al. (2013) MACH14: a multi-site collaboration on ART adherence among 14 institutions. AIDS Behav 17:127-41
Simoni, Jane M; Huh, David; Wilson, Ira B et al. (2012) Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study. J Acquir Immune Defic Syndr 60:466-72
Genberg, Becky L; Wilson, Ira B; Bangsberg, David R et al. (2012) Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS 26:1415-23
Wagner, Glenn J; Goggin, Kathy; Remien, Robert H et al. (2011) A closer look at depression and its relationship to HIV antiretroviral adherence. Ann Behav Med 42:352-60
Miller, Loren G; Golin, Carol E; Liu, Honghu et al. (2004) No evidence of an association between transient HIV viremia (""Blips"") and lower adherence to the antiretroviral medication regimen. J Infect Dis 189:1487-96

Showing the most recent 10 out of 15 publications